ENNATURE
BIOPHARMA

04th November, 2026

The Manager (Listing)
BSE Limited
1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street,
Mumbai – 400 001

Scrip Code: 545012

The Manager (Listing)
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (East),
Mumbai- 400 051

Symbol: ENNATURE

Dear Sirs,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")- Listing of Equity Shares

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed copy of the announcement of the captioned subject.

The information is also available on the Company's website at www.ennaturebiopharma.com.

This is for your information and record.

Thanking you,

Yours truly,
For Ennature Bio Pharma Limited

PREETI CHOUDHARY
Digitally signed by PREETI CHOUDHARY
Date: 2026.11.04 13:41:34 +05'30'

Preeti Choudhary
Company Secretary & Compliance Officer

Ennature Bio Pharma Limited Lists on NSE and BSE on 4th November 2026

The Biopharma division *reports Rs 246 crore in FY26 revenue, with branded nutraceuticals as a key growth driver.*

November 04, 2026: Ennature Bio Pharma Limited listed on the National Stock Exchange of India (NSE) and BSE Limited on 4th of November 2026, bringing its integrated natural ingredients business to the listed market. The company enters this phase with three complementary businesses spanning plant-based pharmaceutical ingredients, biopolymers and nutraceuticals, and a growth strategy centred on expanding its portfolio of science-backed botanical ingredients.

The biopharma division of IGL reported net revenue of Rs 246 crore, EBITDA of Rs 29 crore and a gross margin of 40.1% in FY26. Its business rests on an established plant-based active pharmaceutical ingredients (API) portfolio and a diversified, biopolymer operation, which together provide the foundation for its expansion into branded nutraceuticals. The latter is the company's primary growth driver, with plans to develop higher-value ingredients supported by scientific research, proprietary technologies and clinical validation.

The API business accounts for 67% of sales and includes thiocolchicoside, colchicine, nicotine and vinpocetine. Built over more than 15 years, the business serves over 150 active customers across more than 26 countries, with exports contributing 54% of segment revenues in FY26. Ennature plans to introduce one new API annually, expand its presence in regulated markets and strengthen its nicotine replacement therapy portfolio.

Alongside this established business, Ennature's biopolymer operations provide exposure to a wider range of end markets. The segment, which contributes 16% of sales, focuses on guar gum and speciality gums used across oil and gas, food and beverages, personal care, paints, textiles and supplements. Exports account for 69% of its FY26 revenues, with customers across 23 countries. The company's priorities include developing specialised derivatives, expanding dietary fibre applications and increasing the contribution of higher-value products.

These businesses provide the platform for Ennature's next phase of growth in nutraceuticals, which currently account for 17% of sales. The company is moving beyond standardised botanical extracts towards branded ingredients designed for specific market segments, including women's health, bone and joint health, eye health and metabolic health.

Its portfolio includes five flagship brands: Aspargize, Gingeren, Maxicuma®, Xanthogreen® and Berbisol™. The segment serves more than 90 active customers across over 19 countries, with exports contributing 83% of revenues in FY26. Ennature plans to expand its branded portfolio to six to eight ingredients, strengthen distribution across the US, Europe and Asia, and deepen relationships with leading nutraceutical customers.

The company's approach to this expansion centres on differentiating its ingredients through technology and scientific evidence. Its proprietary platforms - LIMAN™ and SCEMOD™ focus on improving solubility and bio-absorption of ingredients. Ennature reports nine patents filed, five granted patents and four patents under review, alongside a research programme comprising 20 clinical trials. It is also strengthening its international reach, with a local US office supporting customer coverage and stocking capabilities.

Manufacturing capabilities underpin the company's operations across all three segments. Its facilities in Dehradun and Kashipur have manufacturing capacities of 1,600 metric tonnes and 24,000 metric tonnes, respectively. The platform includes supercritical fluid extraction, solvent and aqueous extraction, bio-fermentation and semi-formulation, supported by quality systems and certifications including EU-GMP, CEP's, USFDA and NSF-GMP.

Ennature's growth strategy combines the expansion of its established API portfolio and higher-value biopolymer products with greater investment in branded nutraceuticals. Its listing on NSE and BSE marks a new phase for the business as it seeks to build on its pharmaceutical, research and development and manufacturing expertise to expand its presence in the global natural ingredients market.